

OPEN ACCESS

EDITED AND REVIEWED BY Salvatore Siracusano, University of L'Aquila, Italy

*CORRESPONDENCE
Xiaoying Li

☑ lxylxy13141@163.com

RECEIVED 12 June 2024 ACCEPTED 22 June 2024 PUBLISHED 05 July 2024

CITATION

Li X, Wen J, Li H, Huang Y and Zhou H (2024) Corrigendum: Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: a case report. Front. Oncol. 14:1438794. doi: 10.3389/fonc.2024.1438794

COPYRIGHT

© 2024 Li, Wen, Li, Huang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: a case report

Xiaoying Li*, Jing Wen, Hongtao Li, Yan Huang and Hongliang Zhou

Department of Oncology, the People's Hospital of Yubei District of Chongqing City, Chongqing, China

KEYWORDS

cardiac infarction, PD-1 inhibitor treatment, small cell neuroendocrine carcinoma the ureter, case report, literature review

A Corrigendum on

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: a case report

by Li X, Wen J, Li H, Huang Y and Zhou H (2023). *Front. Oncol.* 13:1114397. doi: 10.3389/fonc.2023.1114397

In the published article, there was an error in Figure 3G as published. We used the wrong image in Figure 3G which is duplicated with Figure 3F. The corrected Figure 3 and its caption "Immunohistochemical results ($400\times$). (A) Hematoxylin and eosin-stained section result; (B) CD56 staining specific for neuroendocrine differentiation; (C) CK-L staining specific for neuroendocrine differentiation; (E) GATA-3 staining specific for neuroendocrine differentiation; (F) Ki-67 staining specific for neuroendocrine differentiation; (G) Syn staining specific for neuroendocrine differentiation; appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Li et al. 10.3389/fonc.2024.1438794




FIGURE 3
Immunohistochemical results (400x). (A) Hematoxylin and eosin-stained section result; (B) CD56 staining specific for neuroendocrine differentiation; (C) CK-L staining specific for neuroendocrine differentiation; (F) CK-pan staining specific for neuroendocrine differentiation; (F) Ki-67 staining specific for neuroendocrine differentiation; (G) Syn staining specific for neuroendocrine differentiation.